In summary, the high expression of SLC31A1 in thyroid papillary carcinoma is associated to poor clinicopathological features and prognosis, and SLC31A1 may become a potential therapeutic target for PTC. This evidence concerns the gene SLC31A1 and differentiated thyroid carcinoma.